Search
Menu
Home
HTB
2002
January
09
HTB
9 January 2002
Contents
Conference reports
41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 16-19 December 2001
Low dose pegylated interferon is ineffective in treating HIV/HCV co-infected patients
Phenotypic resistance to ddI is less frequent than resistance to ZDV, 3TC and abacavir
Impact of Kaletra on amprenavir plasma concentrations in HIV treatment-experienced patients
Immune reconstitution more difficult with low baseline CD4+ T cell counts
HIV-1 may revert to less pathogenic strain a few days after starting HAART
Change from CCR5 to CXCR4 phenotype may affect immunologic responses
ddI EC (Videx) study confirms and clarifies dosing on an empty stomach
Swatch study: should we be cycling drugs?
New HIV drugs, resistance, pharmacogenomics
Antiretroviral therapy
Immunopathogenesis of HIV infection
Basic science and immunology
New findings explain T-cell loss in HIV infection
Other news
Voluntary suspension of Kava-kava sales following safety concerns
The Chapman Clinic: musculoskeletal treatment for patients with HIV
On the web
Additional reports from ICAAC 2001
Double scourge: tuberculosis and HIV coinfection
The road to eradication: is HAART hard enough?
HTB RSS
Current issues
March 2024
February 2024
January 2024
Back issues
Special report
Modelling study challenges links between gender and PrEP: event-based dosing and easier daily dosing should work for all
12 February 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage